Madrigal Pharmaceuticals Inc.

Liver-focused company with Rezdiffra (resmetirom), the first FDA-approved therapy for MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis. Madrigal's THR-beta agonist addresses a large unmet need in a market with an estimated 1.5M+ eligible patients.